Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Abdominal Radiology
Published in: Abdominal Radiology 7/2015

01-10-2015 | Pictorial Essay

FDG PET–CT of gynecologic cancers: pearls and pitfalls

Authors: Hima B. Prabhakar, Jessica J. Kraeft, John O. Schorge, James A. Scott, Susanna I. Lee

Published in: Abdominal Radiology | Issue 7/2015

Login to get access

Abstract

FDG PET–CT plays an important role in treatment planning and in prognosis assessment of gynecologic cancer patients. Detection of hypermetabolic tissue with FDG PET, when combined with the high spatial resolution of CT, results in improved cancer detection and localization not afforded by either modality independently. This article is a primer for a radiologist performing PET–CT on gynecologic cancer patients and includes the imaging protocol, normal pattern of FDG distribution in the female pelvis and the lymph node drainage pathways from the gynecologic organs. Clinically relevant imaging findings that should be included in the report are discussed. Case examples illustrate how potential errors in exam interpretation can be avoided by concurrently performing a high-quality diagnostic CT with the FDG PET scan and by analyzing both the stand-alone and the fusion images.
Literature
1.
Gorospe L, Raman S, Echeveste J, et al. (2005) Whole-body PET/CT: spectrum of physiological variants, artifacts and interpretative pitfalls in cancer patients. Nucl Med Commun 26(8):671–687CrossRefPubMed
2.
Gorospe L, Jover-Diaz R, Vicente-Bartulos A (2012) Spectrum of PET-CT pelvic pitfalls in patients with gynecologic malignancies. Abdom Imaging 37(6):1041–1065CrossRefPubMed
3.
Rahmim A, Zaidi H (2008) PET versus SPECT: strengths, limitations and challenges. Nucl Med Commun 29(3):193–207CrossRefPubMed
4.
Surasi DS, Bhambhvani P, Baldwin JA, Almodovar SE, O’Malley JP (2014) (1)(8)F-FDG PET and PET/CT patient preparation: a review of the literature. J Nucl Med Technol 42(1):5–13CrossRefPubMed
5.
Cronin CG, Prakash P, Blake MA (2010) Oral and IV contrast agents for the CT portion of PET/CT. AJR Am J Roentgenol 195(1):W5–W13CrossRefPubMed
6.
Pfannenberg AC, Aschoff P, Brechtel K, et al. (2007) Value of contrast-enhanced multiphase CT in combined PET/CT protocols for oncological imaging. Br J Radiol 80(954):437–445CrossRefPubMed
7.
Kitajima K, Suzuki K, Senda M, et al. (2011) Preoperative nodal staging of uterine cancer: is contrast-enhanced PET/CT more accurate than non-enhanced PET/CT or enhanced CT alone? Ann Nucl Med 25(7):511–519CrossRefPubMed
8.
Antoch G, Freudenberg LS, Beyer T, Bockisch A, Debatin JF (2004) To enhance or not to enhance? 18F-FDG and CT contrast agents in dual-modality 18F-FDG PET/CT. J Nucl Med 45(Suppl 1):56s–65sPubMed
9.
Prabhakar HB, Sahani DV, Fischman AJ, Mueller PR, Blake MA (2007) Bowel hot spots at PET-CT. Radiographics 27(1):145–159CrossRefPubMed
10.
Kitajima K, Murakami K, Kaji Y, Sugimura K (2010) Spectrum of FDG PET/CT findings of uterine tumors. AJR Am J Roentgenol 195(3):737–743CrossRefPubMed
11.
Liu Y (2009) Benign ovarian and endometrial uptake on FDG PET-CT: patterns and pitfalls. Ann Nucl Med 23(2):107–112CrossRefPubMed
12.
Zhu Z, Wang B, Cheng W, et al. (2006) Endometrial and ovarian F-18 FDG uptake in serial PET studies and the value of delayed imaging for differentiation. Clin Nucl Med 31(12):781–787CrossRefPubMed
13.
Lerman H, Metser U, Grisaru D, et al. (2004) Normal and abnormal 18F-FDG endometrial and ovarian uptake in pre- and postmenopausal patients: assessment by PET/CT. J Nucl Med 45(2):266–271PubMed
14.
Chura JC, Truskinovsky AM, Judson PL, et al. (2007) Positron emission tomography and leiomyomas: clinicopathologic analysis of 3 cases of PET scan-positive leiomyomas and literature review. Gynecol Oncol 104(1):247–252CrossRefPubMed
15.
Kao CH (2003) FDG uptake in a huge uterine myoma. Clin Nucl Med 28(3):249PubMed
16.
Ames J, Blodgett T, Meltzer C (2005) 18F-FDG uptake in an ovary containing a hemorrhagic corpus luteal cyst: false-positive PET/CT in a patient with cervical carcinoma. AJR Am J Roentgenol 185(4):1057–1059CrossRefPubMed
17.
Bagga S (2007) A corpus luteal cyst masquerading as a lymph node mass on PET/CT scan in a pregnant woman with an anterior mediastinal lymphomatous mass. Clin Nucl Med 32(8):649–651CrossRefPubMed
18.
Hricak H, Gatsonis C, Chi DS, et al. (2005) Role of imaging in pretreatment evaluation of early invasive cervical cancer: results of the intergroup study American College of Radiology Imaging Network 6651-Gynecologic Oncology Group 183. J Clin Oncol 23(36):9329–9337CrossRefPubMed
19.
Connor JP, Andrews JI, Anderson B, Buller RE (2000) Computed tomography in endometrial carcinoma. Obstet Gynecol 95(5):692–696CrossRefPubMed
20.
Sironi S, Buda A, Picchio M, et al. (2006) Lymph node metastasis in patients with clinical early-stage cervical cancer: detection with integrated FDG PET/CT. Radiology 238(1):272–279CrossRefPubMed
21.
Antonsen SL, Jensen LN, Loft A, et al. (2013) MRI, PET/CT and ultrasound in the preoperative staging of endometrial cancer—a multicenter prospective comparative study. Gynecol Oncol 128(2):300–308CrossRefPubMed
22.
Cohn DE, Dehdashti F, Gibb RK, et al. (2002) Prospective evaluation of positron emission tomography for the detection of groin node metastases from vulvar cancer. Gynecol Oncol 85(1):179–184CrossRefPubMed
23.
Brown G, Richards CJ, Bourne MW, et al. (2003) Morphologic predictors of lymph node status in rectal cancer with use of high-spatial-resolution MR imaging with histopathologic comparison. Radiology 227(2):371–377CrossRefPubMed
24.
Pecorelli S (2009) Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 105(2):103–104CrossRefPubMed
25.
Koh WJ, Greer BE, Abu-Rustum NR, et al. (2013) Cervical cancer. J Natl Compr Cancer Netw 11(3):320–343
26.
Tirumani SH, Shanbhogue AK, Prasad SR (2013) Current concepts in the diagnosis and management of endometrial and cervical carcinomas. Radiol Clin N Am 51(6):1087–1110CrossRefPubMed
27.
Barter JF, Soong SJ, Shingleton HM, Hatch KD, Orr JW Jr (1989) Complications of combined radical hysterectomy-postoperative radiation therapy in women with early stage cervical cancer. Gynecol Oncol 32(3):292–296CrossRefPubMed
28.
Fiorica JV, Roberts WS, Greenberg H, et al. (1990) Morbidity and survival patterns in patients after radical hysterectomy and postoperative adjuvant pelvic radiotherapy. Gynecol Oncol 36(3):343–347CrossRefPubMed
29.
Pandharipande PV, Choy G, del Carmen MG, et al. (2009) MRI and PET/CT for triaging stage IB clinically operable cervical cancer to appropriate therapy: decision analysis to assess patient outcomes. AJR Am J Roentgenol 192(3):802–814CrossRefPubMed
30.
Stehman FB, Bundy BN, DiSaia PJ, et al. (1991) Carcinoma of the cervix treated with radiation therapy. I. A multi-variate analysis of prognostic variables in the Gynecologic Oncology Group. Cancer 67(11):2776–2785CrossRefPubMed
31.
Patel CN, Nazir SA, Khan Z, Gleeson FV, Bradley KM (2011) 18F-FDG PET/CT of Cervical Carcinoma. Am J Roentgenol 196(5):1225–1233CrossRef
32.
Choi HJ, Roh JW, Seo SS, et al. (2006) Comparison of the accuracy of magnetic resonance imaging and positron emission tomography/computed tomography in the presurgical detection of lymph node metastases in patients with uterine cervical carcinoma: a prospective study. Cancer 106(4):914–922CrossRefPubMed
33.
Grigsby PW, Siegel BA, Dehdashti F, Rader J, Zoberi I (2004) Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome. J Clin Oncol 22(11):2167–2171CrossRefPubMed
34.
Koh WJ, Greer BE, Abu-Rustum NR, et al. (2014) Uterine neoplasms, version 1.2014. J Natl Compr Cancer Netw 12(2):248–280
35.
Mariani A, Dowdy SC, Cliby WA, et al. (2008) Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecol Oncol 109(1):11–18PubMedCentralCrossRefPubMed
36.
Frei KA, Kinkel K (2001) Staging endometrial cancer: role of magnetic resonance imaging. J Magn Reson Imaging 13(6):850–855CrossRefPubMed
37.
Signorelli M, Guerra L, Buda A, et al. (2009) Role of the integrated FDG PET/CT in the surgical management of patients with high risk clinical early stage endometrial cancer: detection of pelvic nodal metastases. Gynecol Oncol 115(2):231–235CrossRefPubMed
38.
Picchio M, Mangili G, Samanes Gajate AM, et al. (2010) High-grade endometrial cancer: value of [(18)F]FDG PET/CT in preoperative staging. Nucl Med Commun 31(6):506–512PubMed
39.
Amit A, Schink J, Reiss A, Lowenstein L (2011) PET/CT in gynecologic cancer: present applications and future prospects—a clinician’s perspective. Obstet Gynecol Clin N Am 38(1):1–21 (vii)CrossRef
40.
Hricak H, Mendelson E, Bohm-Velez M, et al. (2000) Endometrial cancer of the uterus. American College of Radiology. ACR Appropriateness Criteria. Radiology 215(Suppl):947–953PubMed
41.
Mutch DG, Prat J (2014) 2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer. Gynecol Oncol 133(3):401–404CrossRefPubMed
42.
Morgan RJ Jr, Alvarez RD, Armstrong DK, et al. (2013) Ovarian cancer, version 2.2013. J Natl Compr Cancer Netw 11(10):1199–1209
43.
Sebastian S, Lee SI, Horowitz NS, et al. (2008) PET-CT vs. CT alone in ovarian cancer recurrence. Abdom Imaging 33(1):112–118CrossRefPubMed
44.
Mitchell DG, Javitt MC, Glanc P, et al. (2013) ACR appropriateness criteria staging and follow-up of ovarian cancer. J Am Coll Radiol 10(11):822–827CrossRefPubMed
45.
Boellaard R (2009) Standards for PET image acquisition and quantitative data analysis. J Nucl Med 50(Suppl 1):11s–20sCrossRefPubMed
46.
Kapoor V, McCook BM, Torok FS (2004) An introduction to PET-CT imaging. Radiographics 24(2):523–543CrossRefPubMed
47.
Brechtel K, Klein M, Vogel M, et al. (2006) Optimized contrast-enhanced CT protocols for diagnostic whole-body 18F-FDG PET/CT: technical aspects of single-phase versus multiphase CT imaging. J Nucl Med 47(3):470–476PubMed
48.
Blake MA, Singh A, Setty BN, et al. (2006) Pearls and pitfalls in interpretation of abdominal and pelvic PET-CT. Radiographics 26(5):1335–1353CrossRefPubMed
49.
Chen YW, Huang MY, Hou PN, et al. (2009) FDG PET/CT delayed diuretic imaging technique for differentiating invasive pelvic cancer. Clin Nucl Med 34(4):233–235CrossRefPubMed
50.
Koyama K, Okamura T, Kawabe J, et al. (2003) Evaluation of 18F-FDG PET with bladder irrigation in patients with uterine and ovarian tumors. J Nucl Med 44(3):353–358PubMed
Metadata
Title
FDG PET–CT of gynecologic cancers: pearls and pitfalls
Authors
Hima B. Prabhakar
Jessica J. Kraeft
John O. Schorge
James A. Scott
Susanna I. Lee
Publication date
01-10-2015
Publisher
Springer US
Published in
Abdominal Radiology / Issue 7/2015
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-015-0362-7

Other articles of this Issue 7/2015

Abdominal Radiology 7/2015 Go to the issue

OriginalPaper

Effect of radiologists’ experience with an adaptive statistical iterative reconstruction algorithm on detection of hypervascular liver lesions and perception of image quality

Pictorial Essay

Computed tomography after nephron-sparing surgery

OriginalPaper

Value of magnetic resonance imaging in evaluating the pancreatic allograft transplant complications

OriginalPaper

A novel semi-automatic segmentation method for volumetric assessment of the colon based on magnetic resonance imaging

OriginalPaper

Endometrial vs. cervical cancer: development and pilot testing of a magnetic resonance imaging (MRI) scoring system for predicting tumor origin of uterine carcinomas of indeterminate histology

OriginalPaper

Xanthogranulomatous cholecystitis: diagnostic performance of US, CT, and MRI for differentiation from gallbladder carcinoma
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits